Heart and Muscle Metabolism in Barth Syndrome

• Whole-body fatty acid oxidation rate [ Time Frame: baseline ] [ Designated as safety issue: No ]
  Whole-body fatty acid oxidation rate will be measured by 13C-labeled fatty acid stable isotope tracer infusion and mass spectrometry
  
  
• Myocardial fatty acid oxidation rate [ Time Frame: baseline ] [ Designated as safety issue: No ]
  Myocardial fatty acid oxidation rate will be measured by radio-isotope tracer infusion and PET imaging
  
  
• left ventricular systolic strain [ Time Frame: baseline ] [ Designated as safety issue: No ]
  Left ventricular systolic strain will be measured by tissue Doppler echocardiography
  
  

• whole-body amino acid oxidation rate [ Time Frame: baseline ] [ Designated as safety issue: No ]
  whole-body amino acid oxidation rate will be measured by 13C leucine stable isotope tracer infusion and mass spectrometry
  
  
• cardiac energetics [ Time Frame: baseline ] [ Designated as safety issue: No ]
  cardiac energetics will be measured by 31P magnetic resonance spectroscopy of the heart
  
  
• skeletal muscle energetics [ Time Frame: baseline ] [ Designated as safety issue: No ]
  skeletal muscle energetics will be measured by 31P magnetic resonance spectroscopy
  
  

Barth syndrome (BTHS) is an X-linked disorder characterized by abnormal cardiolipin metabolism, mitochondrial dysfunction, muscle wasting and heart failure. BTHS is a particularly significant disease as it is often fatal in childhood and there are no approved therapies for BTHS other than the standard treatment of heart failure. Therefore novel areas of research and platforms in which to test new therapies are highly needed. Through state-of-the-art and innovative methodologies, this project will focus on the novel role of skeletal muscle and heart nutrient (glucose, fatty acid, and amino acid) metabolism in the pathogenesis of BTHS. Phenotypic information regarding skeletal muscle and heart nutrient metabolism in BTHS and how it may relate to energy production and function of these organs is lacking and is significant as this may advance our understanding of the underlying pathogenesis of BTHS. With this understanding, safe and efficacious therapies can be targeted for BTHS. The investigators' overall hypothesis is that impaired fatty acid metabolism in skeletal muscle and the heart produces a fuel deficit in these organs leading to impaired energy production, exercise intolerance and heart failure. Further, as a consequence of impaired fatty acid metabolism in skeletal muscle and the heart, protein breakdown (wasting) in skeletal muscle and the heart occurs to provide amino acids as compensation for this inadequate fatty acid energy supply, thereby worsening heart and skeletal muscle function in BTHS. The investigators' aims to address this hypothesis in 30 young adults and children with BTHS and 30 healthy, age, puberty stage and activity level matched controls ages 8-35 years are:

1) To characterize skeletal muscle and heart nutrient metabolism and 2) To examine the relationship between skeletal muscle and heart nutrient metabolism, energy production and function (exercise tolerance and heart function). As an exploratory aim, we will examine mechanistic molecular pathways of nutrient metabolism; specifically protein breakdown, mitochondrial function and fatty acid metabolism, in human myocytes derived from inducible pluripotent stem cells (from skin fibroblasts) obtained from adults and children with BTHS and from adult controls. Skeletal muscle nutrient metabolism will be quantified by stable-isotope tracer methodology and mass spectrometry, heart nutrient metabolism using radio-isotope tracer methodology and PET imaging, skeletal muscle and heart energy production using magnetic resonance spectroscopy, skeletal muscle function by graded exercise testing and indirect calorimetry, heart function by echocardiography, and myocyte nutrient pathway mechanism examination by pluripotent stem cell induction and protein and RNA expression analyses.